A Phase I/II Trial of Fairly Brief Androgen Suppression and Stereotactic Radiation Therapy for High-Risk Prostate Cancer (FASTR-2): Preliminary Results and Toxicity Analysis

by Laura Callan, MD, MASc, Glenn Bauman, MD, Jeff Chen, PhD, Michael Lock, MD, Tracy Sexton, MD, PhD, David D'Souza, MD, George Rodrigues, MD, PhD
Published 2019-10-01

Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging

by Wei Liu, MD, Katherine Zukotynski, MD, PhD, FRCPC, Louise Emmett, MD, FRACP, Hans T. Chung, MD, FRCPC, Peter Chung, MD, FRCPC, Robert Wolfson, MD, FRCPC, Irina Rachinsky, MD, MSc, FRCPC, Anil Kapoor, MD, FRCSC, Ur Metser, MD, FRCPC, Andrew Loblaw, MD, MSc, FRCPC, Gerard Morton, MB, FRCPC, Tracy Sexton, MD, PhD, FRCPC, Michael Lock, MD, FRCPC, Joelle Helou, MD, MSc, Alejandro Berlin, MD, MSc, Colm Boylan, MB, FRCPC, Susan Archer, BSc, Gregory R. Pond, PhD, PStat, Glenn Bauman, MD, FRCPC
Published 2021-01-01